|
US4196265A
(en)
*
|
1977-06-15 |
1980-04-01 |
The Wistar Institute |
Method of producing antibodies
|
|
US4522811A
(en)
*
|
1982-07-08 |
1985-06-11 |
Syntex (U.S.A.) Inc. |
Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides
|
|
US4469797A
(en)
*
|
1982-09-23 |
1984-09-04 |
Miles Laboratories, Inc. |
Digoxigenin immunogens, antibodies, labeled conjugates, and related derivatives
|
|
US4737462A
(en)
*
|
1982-10-19 |
1988-04-12 |
Cetus Corporation |
Structural genes, plasmids and transformed cells for producing cysteine depleted muteins of interferon-β
|
|
US4966843A
(en)
*
|
1982-11-01 |
1990-10-30 |
Cetus Corporation |
Expression of interferon genes in Chinese hamster ovary cells
|
|
US4816567A
(en)
*
|
1983-04-08 |
1989-03-28 |
Genentech, Inc. |
Recombinant immunoglobin preparations
|
|
NZ210501A
(en)
*
|
1983-12-13 |
1991-08-27 |
Kirin Amgen Inc |
Erythropoietin produced by procaryotic or eucaryotic expression of an exogenous dna sequence
|
|
US4703008A
(en)
*
|
1983-12-13 |
1987-10-27 |
Kiren-Amgen, Inc. |
DNA sequences encoding erythropoietin
|
|
KR850004274A
(ko)
*
|
1983-12-13 |
1985-07-11 |
원본미기재 |
에리트로포이에틴의 제조방법
|
|
US5082658A
(en)
*
|
1984-01-16 |
1992-01-21 |
Genentech, Inc. |
Gamma interferon-interleukin-2 synergism
|
|
EP0158198A1
(en)
|
1984-03-29 |
1985-10-16 |
Takeda Chemical Industries, Ltd. |
DNA and use thereof
|
|
US5807715A
(en)
*
|
1984-08-27 |
1998-09-15 |
The Board Of Trustees Of The Leland Stanford Junior University |
Methods and transformed mammalian lymphocyte cells for producing functional antigen-binding protein including chimeric immunoglobulin
|
|
US4667016A
(en)
*
|
1985-06-20 |
1987-05-19 |
Kirin-Amgen, Inc. |
Erythropoietin purification
|
|
US4690915A
(en)
|
1985-08-08 |
1987-09-01 |
The United States Of America As Represented By The Department Of Health And Human Services |
Adoptive immunotherapy as a treatment modality in humans
|
|
US5679543A
(en)
*
|
1985-08-29 |
1997-10-21 |
Genencor International, Inc. |
DNA sequences, vectors and fusion polypeptides to increase secretion of desired polypeptides from filamentous fungi
|
|
US5643565A
(en)
*
|
1985-09-20 |
1997-07-01 |
Chiron Corporation |
Human IL-2 as a vaccine adjuvant
|
|
US4676980A
(en)
*
|
1985-09-23 |
1987-06-30 |
The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services |
Target specific cross-linked heteroantibodies
|
|
US4935233A
(en)
*
|
1985-12-02 |
1990-06-19 |
G. D. Searle And Company |
Covalently linked polypeptide cell modulators
|
|
DE3712985A1
(de)
|
1987-04-16 |
1988-11-03 |
Hoechst Ag |
Bifunktionelle proteine
|
|
US5359035A
(en)
|
1985-12-21 |
1994-10-25 |
Hoechst Aktiengesellschaft |
Bifunctional proteins including interleukin-2 (IL-2) and granuloctyte macrophage colony stimulating factor (GM-CSF)
|
|
EP0237019A3
(en)
|
1986-03-14 |
1988-03-09 |
Toray Industries, Inc. |
Interferon conjugate and production thereof using recombinant gene
|
|
US5225539A
(en)
*
|
1986-03-27 |
1993-07-06 |
Medical Research Council |
Recombinant altered antibodies and methods of making altered antibodies
|
|
GB8607679D0
(en)
|
1986-03-27 |
1986-04-30 |
Winter G P |
Recombinant dna product
|
|
DK173067B1
(da)
*
|
1986-06-27 |
1999-12-13 |
Univ Washington |
Humant erythropoietin-gen, fremgangsmåde til ekspression deraf i transficerede cellelinier, de transficerede cellelinier sa
|
|
US4894227A
(en)
|
1986-08-01 |
1990-01-16 |
Cetus Corporation |
Composition of immunotoxins with interleukin-2
|
|
US4946778A
(en)
*
|
1987-09-21 |
1990-08-07 |
Genex Corporation |
Single polypeptide chain binding molecules
|
|
US4844893A
(en)
*
|
1986-10-07 |
1989-07-04 |
Scripps Clinic And Research Foundation |
EX vivo effector cell activation for target cell killing
|
|
US5508031A
(en)
*
|
1986-11-21 |
1996-04-16 |
Cetus Oncology Corporation |
Method for treating biological damage using a free-radial scavenger and interleukin-2
|
|
US4732683A
(en)
*
|
1986-12-02 |
1988-03-22 |
Biospectrum, Inc. |
Purification method for alpha interferon
|
|
US5019368A
(en)
*
|
1989-02-23 |
1991-05-28 |
Cancer Biologics, Inc. |
Detection of necrotic malignant tissue and associated therapy
|
|
EP0307434B2
(en)
*
|
1987-03-18 |
1998-07-29 |
Scotgen Biopharmaceuticals, Inc. |
Altered antibodies
|
|
US5258498A
(en)
*
|
1987-05-21 |
1993-11-02 |
Creative Biomolecules, Inc. |
Polypeptide linkers for production of biosynthetic proteins
|
|
US5091513A
(en)
*
|
1987-05-21 |
1992-02-25 |
Creative Biomolecules, Inc. |
Biosynthetic antibody binding sites
|
|
ATE243754T1
(de)
|
1987-05-21 |
2003-07-15 |
Micromet Ag |
Multifunktionelle proteine mit vorbestimmter zielsetzung
|
|
DE3853740T2
(de)
|
1987-06-10 |
1995-11-09 |
Dana Farber Cancer Inst Inc |
Bifunktionelle Antikörperkonstruktionen und Verfahren zur selektiven Tötung von Zellbeständen.
|
|
US5064646A
(en)
|
1988-08-02 |
1991-11-12 |
The University Of Maryland |
Novel infectious bursal disease virus
|
|
EP0305967B1
(de)
|
1987-09-02 |
1993-05-05 |
Ciba-Geigy Ag |
Konjugate von Interferon alpha mit Immunglobulinen
|
|
JP2755395B2
(ja)
|
1987-09-23 |
1998-05-20 |
ブリストル―マイアーズ スクイブ コムパニー |
Ｈｉｖ感染細胞に殺作用する抗体異種結合体
|
|
NZ226414A
(en)
|
1987-10-02 |
1992-07-28 |
Genentech Inc |
Cd4 peptide adhesion variants and their preparation and use
|
|
PT89121A
(pt)
|
1987-12-04 |
1989-12-29 |
Du Pont |
Processo para a preparacao de interleuquina-2 imobilizada e interleuquina-2 contendo uma extensao no terminal-carboxilo com actividade de interleuquina-2 natural
|
|
JP3040121B2
(ja)
*
|
1988-01-12 |
2000-05-08 |
ジェネンテク，インコーポレイテッド |
増殖因子レセプターの機能を阻害することにより腫瘍細胞を処置する方法
|
|
CA1341588C
(en)
|
1988-01-26 |
2009-01-06 |
Michel Revel |
Human ifn-beta2/i1-6, its purification and use
|
|
US5120525A
(en)
*
|
1988-03-29 |
1992-06-09 |
Immunomedics, Inc. |
Radiolabeled antibody cytotoxic therapy of cancer
|
|
US4975369A
(en)
|
1988-04-21 |
1990-12-04 |
Eli Lilly And Company |
Recombinant and chimeric KS1/4 antibodies directed against a human adenocarcinoma antigen
|
|
IE62463B1
(en)
|
1988-07-07 |
1995-02-08 |
Res Dev Foundation |
Immunoconjugates for cancer diagnosis and therapy
|
|
US5601819A
(en)
*
|
1988-08-11 |
1997-02-11 |
The General Hospital Corporation |
Bispecific antibodies for selective immune regulation and for selective immune cell binding
|
|
US5457038A
(en)
*
|
1988-11-10 |
1995-10-10 |
Genetics Institute, Inc. |
Natural killer stimulatory factor
|
|
US5242824A
(en)
|
1988-12-22 |
1993-09-07 |
Oncogen |
Monoclonal antibody to human carcinomas
|
|
US5530101A
(en)
|
1988-12-28 |
1996-06-25 |
Protein Design Labs, Inc. |
Humanized immunoglobulins
|
|
US5116964A
(en)
*
|
1989-02-23 |
1992-05-26 |
Genentech, Inc. |
Hybrid immunoglobulins
|
|
US5225538A
(en)
*
|
1989-02-23 |
1993-07-06 |
Genentech, Inc. |
Lymphocyte homing receptor/immunoglobulin fusion proteins
|
|
US5703055A
(en)
|
1989-03-21 |
1997-12-30 |
Wisconsin Alumni Research Foundation |
Generation of antibodies through lipid mediated DNA delivery
|
|
US5166322A
(en)
|
1989-04-21 |
1992-11-24 |
Genetics Institute |
Cysteine added variants of interleukin-3 and chemical modifications thereof
|
|
ZA902949B
(en)
|
1989-05-05 |
1992-02-26 |
Res Dev Foundation |
A novel antibody delivery system for biological response modifiers
|
|
US6291158B1
(en)
*
|
1989-05-16 |
2001-09-18 |
Scripps Research Institute |
Method for tapping the immunological repertoire
|
|
US5399346A
(en)
*
|
1989-06-14 |
1995-03-21 |
The United States Of America As Represented By The Department Of Health And Human Services |
Gene therapy
|
|
ATE123065T1
(de)
*
|
1989-07-07 |
1995-06-15 |
Takeda Chemical Industries Ltd |
Proteine und deren herstellung.
|
|
US5073627A
(en)
|
1989-08-22 |
1991-12-17 |
Immunex Corporation |
Fusion proteins comprising GM-CSF and IL-3
|
|
US5196320A
(en)
*
|
1989-09-20 |
1993-03-23 |
Abbott Biotech, Inc. |
Method of producing engineered binding proteins
|
|
AU646822B2
(en)
|
1989-10-13 |
1994-03-10 |
Kirin-Amgen Inc. |
Erythropoietin isoforms
|
|
US5856298A
(en)
*
|
1989-10-13 |
1999-01-05 |
Amgen Inc. |
Erythropoietin isoforms
|
|
US5859205A
(en)
|
1989-12-21 |
1999-01-12 |
Celltech Limited |
Humanised antibodies
|
|
EP0790309B1
(en)
|
1989-12-22 |
2007-07-25 |
F. Hoffmann-La Roche Ag |
Cytotoxic lymphocyte maturation factor 40kD subunit and monoclonal antibodies directed thereto
|
|
US5314995A
(en)
*
|
1990-01-22 |
1994-05-24 |
Oncogen |
Therapeutic interleukin-2-antibody based fusion proteins
|
|
US5349053A
(en)
*
|
1990-06-01 |
1994-09-20 |
Protein Design Labs, Inc. |
Chimeric ligand/immunoglobulin molecules and their uses
|
|
US7253264B1
(en)
|
1990-06-28 |
2007-08-07 |
Sanofi-Arentideutschland GmbH |
Immunoglobulin fusion proteins, their production and use
|
|
WO1992005209A1
(en)
*
|
1990-09-18 |
1992-04-02 |
Akzo N.V. |
Copolymerization process and optical copolymer produced therefrom
|
|
US5650150A
(en)
|
1990-11-09 |
1997-07-22 |
Gillies; Stephen D. |
Recombinant antibody cytokine fusion proteins
|
|
FR2670039B1
(fr)
*
|
1990-11-29 |
1993-12-24 |
Commissariat A Energie Atomique |
Procede et dispositif de reconstruction d'images tridimentionnelles d'un objet en utilisant deux trajectoires circulaires d'acquisition.
|
|
US5709859A
(en)
*
|
1991-01-24 |
1998-01-20 |
Bristol-Myers Squibb Company |
Mixed specificity fusion proteins
|
|
US6072039A
(en)
|
1991-04-19 |
2000-06-06 |
Rohm And Haas Company |
Hybrid polypeptide comparing a biotinylated avidin binding polypeptide fused to a polypeptide of interest
|
|
EP0519596B1
(en)
|
1991-05-17 |
2005-02-23 |
Merck & Co. Inc. |
A method for reducing the immunogenicity of antibody variable domains
|
|
US6797492B2
(en)
*
|
1991-05-17 |
2004-09-28 |
Merck & Co., Inc. |
Method for reducing the immunogenicity of antibody variable domains
|
|
US5199942A
(en)
*
|
1991-06-07 |
1993-04-06 |
Immunex Corporation |
Method for improving autologous transplantation
|
|
ATE255131T1
(de)
|
1991-06-14 |
2003-12-15 |
Genentech Inc |
Humanisierter heregulin antikörper
|
|
WO1994004679A1
(en)
|
1991-06-14 |
1994-03-03 |
Genentech, Inc. |
Method for making humanized antibodies
|
|
AU666866B2
(en)
|
1991-08-30 |
1996-02-29 |
Fred Hutchinson Cancer Research Center |
Hybrid cytokines
|
|
US20020037558A1
(en)
*
|
1991-10-23 |
2002-03-28 |
Kin-Ming Lo |
E.coli produced immunoglobulin constructs
|
|
DE69228264T2
(de)
*
|
1991-11-25 |
1999-08-05 |
Sharp K.K., Osaka |
Vorrichtung zur Weiterverarbeitung nach der Kopierung
|
|
US6627615B1
(en)
*
|
1991-12-17 |
2003-09-30 |
The Regents Of The University Of California |
Methods and compositions for in vivo gene therapy
|
|
RU94045919A
(ru)
|
1992-02-06 |
1996-11-10 |
Шеринг Корпорейшн (US) |
Антитела, клетки, полипептид, днк векторы, способ получения полипептида, способ получения антитела, фармацевтическая композиция
|
|
US5593874A
(en)
*
|
1992-03-19 |
1997-01-14 |
Monsanto Company |
Enhanced expression in plants
|
|
CA2133409C
(en)
*
|
1992-04-01 |
2011-05-24 |
Ralph M. Steinman |
Method for in vitro proliferation of dendritic cell precursors and their use to produce immunogens
|
|
ATE311895T1
(de)
*
|
1992-05-26 |
2005-12-15 |
Immunex Corp |
Neue zytokine die cd30 binden
|
|
WO1993024640A2
(en)
*
|
1992-06-04 |
1993-12-09 |
The Regents Of The University Of California |
Methods and compositions for in vivo gene therapy
|
|
US5614184A
(en)
*
|
1992-07-28 |
1997-03-25 |
New England Deaconess Hospital |
Recombinant human erythropoietin mutants and therapeutic methods employing them
|
|
EP0671926B1
(en)
*
|
1992-08-11 |
2002-11-13 |
President And Fellows Of Harvard College |
Immunomodulatory peptides
|
|
DE4228839A1
(de)
|
1992-08-29 |
1994-03-03 |
Behringwerke Ag |
Verfahren zum Nachweis und zur Bestimmung von Mediatoren
|
|
CA2126967A1
(en)
*
|
1992-11-04 |
1994-05-11 |
Anna M. Wu |
Novel antibody construct
|
|
PT668777E
(pt)
*
|
1992-11-05 |
2007-01-31 |
Sloan Kettering Inst Cancer |
Antigenio de membrana especifico para a prostata
|
|
US5738849A
(en)
*
|
1992-11-24 |
1998-04-14 |
G. D. Searle & Co. |
Interleukin-3 (IL-3) variant fusion proteins, their recombinant production, and therapeutic compositions comprising them
|
|
US5543297A
(en)
*
|
1992-12-22 |
1996-08-06 |
Merck Frosst Canada, Inc. |
Human cyclooxygenase-2 cDNA and assays for evaluating cyclooxygenase-2 activity
|
|
US6096331A
(en)
*
|
1993-02-22 |
2000-08-01 |
Vivorx Pharmaceuticals, Inc. |
Methods and compositions useful for administration of chemotherapeutic agents
|
|
AU6816194A
(en)
*
|
1993-04-20 |
1994-11-08 |
Robinson, William S. |
Methods and materials for treatment of individuals infected with intracellular infectious agents
|
|
US5759551A
(en)
*
|
1993-04-27 |
1998-06-02 |
United Biomedical, Inc. |
Immunogenic LHRH peptide constructs and synthetic universal immune stimulators for vaccines
|
|
AU697453B2
(en)
*
|
1993-04-29 |
1998-10-08 |
Abbott Laboratories |
Erythropoietin analog compositions and methods
|
|
US5554512A
(en)
|
1993-05-24 |
1996-09-10 |
Immunex Corporation |
Ligands for flt3 receptors
|
|
CA2125763C
(en)
*
|
1993-07-02 |
2007-08-28 |
Maurice Kent Gately |
P40 homodimer of interleukin-12
|
|
GB2280171B
(en)
*
|
1993-07-22 |
1996-12-18 |
Cargo Unit Containers Ltd |
Improvments in or relating to freight containers
|
|
IL192290A0
(en)
|
1993-08-17 |
2008-12-29 |
Kirin Amgen Inc |
Erythropoietin analogs
|
|
JP4115517B2
(ja)
*
|
1994-01-25 |
2008-07-09 |
エラン ファーマシューティカルズ， インコーポレイテッド |
白血球付着分子 ｖｌａ−４に対するヒト化抗体
|
|
NZ285501A
(en)
*
|
1994-04-26 |
1998-02-26 |
Childrens Medical Center |
Plasminogen analogs (angiostatin), endothelial inhibitors, assays and kits
|
|
US5837682A
(en)
*
|
1996-03-08 |
1998-11-17 |
The Children's Medical Center Corporation |
Angiostatin fragments and method of use
|
|
US5639725A
(en)
*
|
1994-04-26 |
1997-06-17 |
Children's Hospital Medical Center Corp. |
Angiostatin protein
|
|
CU22615A1
(es)
|
1994-06-30 |
2000-02-10 |
Centro Inmunologia Molecular |
Procedimiento de obtención de anticuerpos monoclonales murinos menos inmunogénicos. anticuerpos monoclonales obtenidos
|
|
US6429199B1
(en)
*
|
1994-07-15 |
2002-08-06 |
University Of Iowa Research Foundation |
Immunostimulatory nucleic acid molecules for activating dendritic cells
|
|
US6309853B1
(en)
|
1994-08-17 |
2001-10-30 |
The Rockfeller University |
Modulators of body weight, corresponding nucleic acids and proteins, and diagnostic and therapeutic uses thereof
|
|
US5541087A
(en)
*
|
1994-09-14 |
1996-07-30 |
Fuji Immunopharmaceuticals Corporation |
Expression and export technology of proteins as immunofusins
|
|
ES2167391T3
(es)
|
1994-09-16 |
2002-05-16 |
Merck Patent Gmbh |
Inmunoconjugados ii.
|
|
US6309636B1
(en)
*
|
1995-09-14 |
2001-10-30 |
Cancer Research Institute Of Contra Costa |
Recombinant peptides derived from the Mc3 anti-BA46 antibody, methods of use thereof, and methods of humanizing antibody peptides
|
|
US6086875A
(en)
*
|
1995-01-17 |
2000-07-11 |
The Brigham And Women's Hospital, Inc. |
Receptor specific transepithelial transport of immunogens
|
|
US6485726B1
(en)
|
1995-01-17 |
2002-11-26 |
The Brigham And Women's Hospital, Inc. |
Receptor specific transepithelial transport of therapeutics
|
|
US5935821A
(en)
*
|
1995-01-17 |
1999-08-10 |
Board Of Trustees Of The University Of Kentucky |
Polynucleotides related to monoclonal antibody 1A7 and use for the treatment of melanoma and small cell carcinoma
|
|
US5691309A
(en)
*
|
1995-01-31 |
1997-11-25 |
Eli Lilly And Company |
Anti-obesity proteins
|
|
US5552524A
(en)
*
|
1995-01-31 |
1996-09-03 |
Eli Lilly And Company |
Anti-obesity proteins
|
|
US5891680A
(en)
*
|
1995-02-08 |
1999-04-06 |
Whitehead Institute For Biomedical Research |
Bioactive fusion proteins comprising the p35 and p40 subunits of IL-12
|
|
WO1996028548A1
(en)
*
|
1995-03-10 |
1996-09-19 |
Genentech, Inc. |
Receptor activation by gas6
|
|
US5719266A
(en)
*
|
1995-03-17 |
1998-02-17 |
Eli Lilly And Company |
Anti-obesity proteins
|
|
US6281010B1
(en)
*
|
1995-06-05 |
2001-08-28 |
The Trustees Of The University Of Pennsylvania |
Adenovirus gene therapy vehicle and cell line
|
|
WO1997002004A2
(en)
*
|
1995-06-30 |
1997-01-23 |
Eli Lilly And Company |
Methods for treating diabetes
|
|
AU724856B2
(en)
*
|
1995-06-30 |
2000-10-05 |
Mochida Pharmaceutical Co., Ltd. |
Anti-Fas ligand antibody and assay method using the anti-Fas ligand antibody
|
|
US6406689B1
(en)
*
|
1995-10-03 |
2002-06-18 |
Frank W. Falkenberg |
Compositions and methods for treatment of tumors and metastatic diseases
|
|
US5854205A
(en)
|
1995-10-23 |
1998-12-29 |
The Children's Medical Center Corporation |
Therapeutic antiangiogenic compositions and methods
|
|
US5723125A
(en)
*
|
1995-12-28 |
1998-03-03 |
Tanox Biosystems, Inc. |
Hybrid with interferon-alpha and an immunoglobulin Fc linked through a non-immunogenic peptide
|
|
US6080409A
(en)
*
|
1995-12-28 |
2000-06-27 |
Dendreon Corporation |
Immunostimulatory method
|
|
US6750334B1
(en)
*
|
1996-02-02 |
2004-06-15 |
Repligen Corporation |
CTLA4-immunoglobulin fusion proteins having modified effector functions and uses therefor
|
|
US5834597A
(en)
*
|
1996-05-20 |
1998-11-10 |
Protein Design Labs, Inc. |
Mutated nonactivating IgG2 domains and anti CD3 antibodies incorporating the same
|
|
CA2205757C
(en)
*
|
1996-05-30 |
2006-01-24 |
F. Hoffmann-La Roche Ag |
Pyridazinone derivatives and their use as inhibitors of prostaglandin g/h synthase i and ii(cox i and ii)
|
|
US5922685A
(en)
*
|
1996-06-05 |
1999-07-13 |
Powderject Vaccines, Inc. |
IL-12 gene therapy of tumors
|
|
US6777540B1
(en)
*
|
1996-09-02 |
2004-08-17 |
Ko Okumura |
Humanized immunoglobulin reacting specifically with Fas ligand or active fragments thereof and region inducing apoptosis originating in Fas ligand
|
|
ES2176574T3
(es)
*
|
1996-09-03 |
2002-12-01 |
Gsf Forschungszentrum Umwelt |
Utilizacion de anticuerpos bi y triespecificos para la induccion de inmunidad tumoral.
|
|
US6417337B1
(en)
|
1996-10-31 |
2002-07-09 |
The Dow Chemical Company |
High affinity humanized anti-CEA monoclonal antibodies
|
|
US5994104A
(en)
*
|
1996-11-08 |
1999-11-30 |
Royal Free Hospital School Of Medicine |
Interleukin-12 fusion protein
|
|
US6100387A
(en)
*
|
1997-02-28 |
2000-08-08 |
Genetics Institute, Inc. |
Chimeric polypeptides containing chemokine domains
|
|
US6277375B1
(en)
|
1997-03-03 |
2001-08-21 |
Board Of Regents, The University Of Texas System |
Immunoglobulin-like domains with increased half-lives
|
|
PT973550E
(pt)
*
|
1997-04-11 |
2003-01-31 |
Searle & Co |
Anticorpos antagonistas anti-integrina avb3
|
|
JP2002512624A
(ja)
*
|
1997-05-21 |
2002-04-23 |
バイオベーション リミテッド |
非免疫原性タンパク質の製造方法
|
|
ES2590912T3
(es)
|
1997-12-08 |
2016-11-24 |
Merck Patent Gmbh |
Proteínas de fusión heterodiméricas útiles para inmunoterapia dirigida y estimulación general del sistema inmunitario
|
|
US20030105294A1
(en)
|
1998-02-25 |
2003-06-05 |
Stephen Gillies |
Enhancing the circulating half life of antibody-based fusion proteins
|
|
EP1071469A2
(en)
*
|
1998-04-17 |
2001-01-31 |
Lexigen Pharmaceuticals Corp. |
Enhancement of antibody-cytokine fusion protein mediated immune responses by co-administration with prostaglandin inhibitor
|
|
US6284536B1
(en)
|
1998-04-20 |
2001-09-04 |
The Regents Of The University Of California |
Modified immunoglobin molecules and methods for use thereof
|
|
WO1999058662A1
(fr)
|
1998-05-14 |
1999-11-18 |
Merck Patent Gmbh |
Proteine fusionnee
|
|
US6620382B1
(en)
*
|
1998-05-22 |
2003-09-16 |
Biopheresis Technologies, Llc. |
Method and compositions for treatment of cancers
|
|
US20020142374A1
(en)
|
1998-08-17 |
2002-10-03 |
Michael Gallo |
Generation of modified molecules with increased serum half-lives
|
|
DE69942207D1
(de)
*
|
1998-08-25 |
2010-05-12 |
Merck Patent Gmbh |
Expression und export von angiostatin und endostatin als immunofusins
|
|
US6646113B1
(en)
|
1998-09-17 |
2003-11-11 |
The Trustees Of The University Of Pennsylvania |
Nucleic acid molecule encoding human survival of motor neuron-interacting protein 1 (SIP1) deletion mutants
|
|
US6335176B1
(en)
*
|
1998-10-16 |
2002-01-01 |
Pharmacopeia, Inc. |
Incorporation of phosphorylation sites
|
|
EP1051432B1
(en)
|
1998-12-08 |
2007-01-24 |
Biovation Limited |
Method for reducing immunogenicity of proteins
|
|
CA2356401A1
(en)
*
|
1999-01-07 |
2000-07-13 |
Lexigen Pharmaceuticals, Corp. |
Expression and export of anti-obesity proteins as fc fusion proteins
|
|
US6342219B1
(en)
|
1999-04-28 |
2002-01-29 |
Board Of Regents, The University Of Texas System |
Antibody compositions for selectively inhibiting VEGF
|
|
KR100922809B1
(ko)
|
1999-05-06 |
2009-10-21 |
웨이크 포리스트 유니버시티 |
면역 반응을 유발하는 항원을 동정하기 위한 조성물과 방법
|
|
US6348192B1
(en)
*
|
1999-05-11 |
2002-02-19 |
Bayer Corporation |
Interleukin-2 mutein expressed from mammalian cells
|
|
RU2262510C9
(ru)
*
|
1999-05-19 |
2006-04-20 |
Лексиген Фармасьютикэлс Корп. |
Слитый белок, обладающий биологической активностью интерферона-альфа, димерный слитый белок, фармацевтическая композиция, их содержащая, молекула днк (варианты) и способ адресования интерферона-альфа в ткани печени
|
|
CZ299516B6
(cs)
*
|
1999-07-02 |
2008-08-20 |
F. Hoffmann-La Roche Ag |
Konjugát erythropoetinového glykoproteinu, zpusobjeho výroby a použití a farmaceutická kompozice sjeho obsahem
|
|
PE20010288A1
(es)
*
|
1999-07-02 |
2001-03-07 |
Hoffmann La Roche |
Derivados de eritropoyetina
|
|
RU2263118C2
(ru)
|
1999-08-09 |
2005-10-27 |
Лексиген Фармасьютикэлс Корп. |
Комплексы антител с несколькими цитокинами
|
|
WO2001023573A1
(fr)
*
|
1999-09-30 |
2001-04-05 |
Kyowa Hakko Kogyo Co., Ltd. |
Anticorps transplantes a domaine de determination de complementation de type humain, dresse contre le ganglioside gd2, et derive de cet anticorps
|
|
DK1252192T3
(da)
|
2000-02-11 |
2006-11-20 |
Merck Patent Gmbh |
Forbedring af antistofbaserede fusionsproteiners serumhalveringstid
|
|
PT1719528E
(pt)
*
|
2000-02-24 |
2012-01-06 |
Philogen Spa |
Composições e métodos para tratamento de angiogénese em lesões patológicas
|
|
US6586398B1
(en)
*
|
2000-04-07 |
2003-07-01 |
Amgen, Inc. |
Chemically modified novel erythropoietin stimulating protein compositions and methods
|
|
CA2407707A1
(en)
*
|
2000-05-12 |
2001-11-22 |
Neose Technologies, Inc. |
In vitro fucosylation recombinant glycopeptides
|
|
SK982003A3
(en)
*
|
2000-06-29 |
2004-05-04 |
Merck Patent Gmbh |
Enhancement of antibody-cytokine fusion protein mediated immune responses by combined treatment with immunocytokine uptake enhancing agents
|
|
KR20030067755A
(ko)
*
|
2001-01-18 |
2003-08-14 |
메르크 파텐트 게엠베하 |
글루코세레브로시다제 활성을 갖는 이관능성 융합 단백질
|
|
CA2438628A1
(en)
*
|
2001-02-19 |
2002-08-29 |
Merck Patent Gesellschaft Mit Beschraenkter Haftung |
Artificial proteins with reduced immunogenicity
|
|
US7148321B2
(en)
|
2001-03-07 |
2006-12-12 |
Emd Lexigen Research Center Corp. |
Expression technology for proteins containing a hybrid isotype antibody moiety
|
|
WO2002079415A2
(en)
|
2001-03-30 |
2002-10-10 |
Lexigen Pharmaceuticals Corp. |
Reducing the immunogenicity of fusion proteins
|
|
ES2361664T3
(es)
*
|
2001-05-03 |
2011-06-21 |
Merck Patent Gmbh |
Anticuerpo recombinante para tumor específico y su utilización.
|
|
AU2002357784B2
(en)
|
2001-12-04 |
2008-07-31 |
Merck Patent Gmbh |
Immunocytokines with modulated selectivity
|
|
US6996009B2
(en)
*
|
2002-06-21 |
2006-02-07 |
Micron Technology, Inc. |
NOR flash memory cell with high storage density
|
|
BRPI0317376B8
(pt)
|
2002-12-17 |
2021-05-25 |
Merck Patent Gmbh |
proteína de fusão de anticorpo-il2 designada como hu14.18-il2, usos da mesma, vetor e composição farmacêutica
|
|
US9395802B2
(en)
|
2014-05-22 |
2016-07-19 |
Via Alliance Semiconductor Co., Ltd. |
Multi-core data array power gating restoral mechanism
|